Nowadays, there is a need for identification and production of new antigens, common for one or more genera of Gram-negative bacteria, especially bacterial strains causing nosocomial infections, e.g. Shigella spp., Salmonella spp., Klebsiella spp., Serratia spp., Enterobacter and E. coli. Those antigens could be used for efficient prevention of disases, such as nosocomial infections, septic shock and enteric infections. Therefore, it would be highly beneficial to develop a vaccine/therapeutic composition based on such common antigen against a broad range of Gram-negative bacteria.
For the commercialisation, we offer an isolated immunogenic antigen, glycoconjugates of this antigen with the protein, compositions and vaccines containing such antigen/glyco- conjugate for prophylaxis and treatment of infections caused by Gram-negative bacteria.
The antigen of the invention has the advantage of being common for a broad repertoire of bacterial strains causing nosocomial infections, therefore it is especially suitable for the production of vaccines against those strains. It causes the generation of broadly cross-reactive antibodies, antibacterial antibodies, as well as antibodies with anti-endotoxin activity.
- Pharmaceutical composition for treatment of selected bacterial diseases caused by Gram-negative genera e.g. nosocomial infections
- Vaccine containing glycoconjugate of the invention against selected Enterobacteriaceae bacteria
Posted by Agata Kołacz, Posted on 20.05.2016